442 related articles for article (PubMed ID: 33408195)
1. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms.
Loo J; Spittle DA; Newnham M
Thorax; 2021 Apr; 76(4):412-420. PubMed ID: 33408195
[TBL] [Abstract][Full Text] [Related]
2. Pulmonary Thrombosis and Thromboembolism in COVID-19.
Poor HD
Chest; 2021 Oct; 160(4):1471-1480. PubMed ID: 34153340
[TBL] [Abstract][Full Text] [Related]
3. [COVID-19 and venous thromboembolism].
Trimaille A; Bonnet G
Ann Cardiol Angeiol (Paris); 2020 Dec; 69(6):370-375. PubMed ID: 33081917
[TBL] [Abstract][Full Text] [Related]
4. Role of SARS-CoV-2 -induced cytokines and growth factors in coagulopathy and thromboembolism.
Ahmad F; Kannan M; Ansari AW
Cytokine Growth Factor Rev; 2022 Feb; 63():58-68. PubMed ID: 34750061
[TBL] [Abstract][Full Text] [Related]
5. ABO Blood Group, SARS-CoV-2 Infection, and Risk of Venous Thromboembolism: Population-Based Cohort Study.
Ray JG; Vermeulen MJ; Schull MJ; Park AL
Clin Appl Thromb Hemost; 2021; 27():10760296211008986. PubMed ID: 33827287
[No Abstract] [Full Text] [Related]
6. Mechanisms of COVID-19 Associated Pulmonary Thrombosis: A Narrative Review.
Niculae CM; Hristea A; Moroti R
Biomedicines; 2023 Mar; 11(3):. PubMed ID: 36979908
[TBL] [Abstract][Full Text] [Related]
7. [COVID-19: Coagulopathy and thrombosis].
Tazi Mezalek Z
Rev Med Interne; 2021 Feb; 42(2):93-100. PubMed ID: 33509669
[TBL] [Abstract][Full Text] [Related]
8. IL-1 induces throboxane-A2 (TxA2) in COVID-19 causing inflammation and micro-thrombi: inhibitory effect of the IL-1 receptor antagonist (IL-1Ra).
Conti P; Caraffa A; Gallenga CE; Ross R; Kritas SK; Frydas I; Younes A; Di Emidio P; Ronconi G; Toniato E
J Biol Regul Homeost Agents; 2020 Sep-Oct,; 34(5):1623-1627. PubMed ID: 32744052
[TBL] [Abstract][Full Text] [Related]
9. A Review of Venous Thromboembolism Phenomena in COVID-19 Patients.
Kermani-Alghoraishi M; Ghahramani R
Curr Probl Cardiol; 2021 Mar; 46(3):100692. PubMed ID: 32994052
[TBL] [Abstract][Full Text] [Related]
10. D-Dimer, Fibrinogen, and IL-6 in COVID-19 Patients with Suspected Venous Thromboembolism: A Narrative Review.
Eljilany I; Elzouki AN
Vasc Health Risk Manag; 2020; 16():455-462. PubMed ID: 33223833
[TBL] [Abstract][Full Text] [Related]
11. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications.
Lim MS; Mcrae S
Crit Rev Oncol Hematol; 2021 Dec; 168():103529. PubMed ID: 34800652
[TBL] [Abstract][Full Text] [Related]
12. Venous thromboembolism in the era of COVID-19.
Kyriakoulis KG; Kokkinidis DG; Kyprianou IA; Papanastasiou CA; Archontakis-Barakakis P; Doundoulakis I; Bakoyiannis C; Giannakoulas G; Palaiodimos L
Phlebology; 2021 Mar; 36(2):91-99. PubMed ID: 33249999
[TBL] [Abstract][Full Text] [Related]
13. Thromboinflammation as a Driver of Venous Thromboembolism.
Gauchel N; Krauel K; Hamad MA; Bode C; Duerschmied D
Hamostaseologie; 2021 Dec; 41(6):428-432. PubMed ID: 34942655
[TBL] [Abstract][Full Text] [Related]
14. Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019.
Petito E; Falcinelli E; Paliani U; Cesari E; Vaudo G; Sebastiano M; Cerotto V; Guglielmini G; Gori F; Malvestiti M; Becattini C; Paciullo F; De Robertis E; Bury L; Lazzarini T; Gresele P;
J Infect Dis; 2021 Mar; 223(6):933-944. PubMed ID: 33280009
[TBL] [Abstract][Full Text] [Related]
15. [COVID-19-associated coagulopathy].
Morishita E
Rinsho Ketsueki; 2021; 62(8):1236-1246. PubMed ID: 34497212
[TBL] [Abstract][Full Text] [Related]
16. A critical review of the pathophysiology of thrombotic complications and clinical practice recommendations for thromboprophylaxis in pregnant patients with COVID-19.
D'Souza R; Malhamé I; Teshler L; Acharya G; Hunt BJ; McLintock C
Acta Obstet Gynecol Scand; 2020 Sep; 99(9):1110-1120. PubMed ID: 32678949
[TBL] [Abstract][Full Text] [Related]
17. Heterogeneity in reporting venous thromboembolic phenotypes in COVID-19: methodological issues and clinical implications.
Kollias A; Kyriakoulis KG; Stergiou GS; Syrigos K
Br J Haematol; 2020 Aug; 190(4):529-532. PubMed ID: 32621757
[TBL] [Abstract][Full Text] [Related]
18. The use of antiplatelet agents for arterial thromboprophylaxis in COVID-19.
Kow CS; Hasan SS
Rev Esp Cardiol (Engl Ed); 2021 Jan; 74(1):114-115. PubMed ID: 32933883
[No Abstract] [Full Text] [Related]
19. COVID-19 Infection in Critically Ill Patients Carries a High Risk of Venous Thrombo-embolism.
Bellmunt-Montoya S; Riera C; Gil D; Rodríguez M; García-Reyes M; Martínez-Carnovale L; Marrero C; Gil M; Ruiz-Rodríguez JC; Ferrer R; de Nadal M; Monreal M; Llagostera S
Eur J Vasc Endovasc Surg; 2021 Apr; 61(4):628-634. PubMed ID: 33583710
[TBL] [Abstract][Full Text] [Related]
20. Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: cause of disease or epiphenomenon?
Pavoni V; Gianesello L; Horton A
J Thromb Thrombolysis; 2021 Aug; 52(2):542-552. PubMed ID: 33973157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
